The complaint centers on allegations that Regeneron violated the Securities Exchange Act of 1934 by disseminating false and misleading information. According to the litigation filing, the company suggested that its Fianlimab-Libtayo study was positioned to reach its primary endpoint. However, the firm contends that Regeneron relied on flawed statistical assumptions and failed to demonstrate any meaningful clinical differentiation from existing therapies available on the market.

Shareholders who incurred losses during the identified class period have until September 14, 2026, to contact the Schall Law Firm to participate in the proceedings. While the class has not yet been formally certified, legal representatives are soliciting inquiries to discuss individual rights. Investors who choose not to take action remain absent class members, meaning they are currently not represented by counsel in the ongoing legal challenge against the company.